financetom
Business
financetom
/
Business
/
FDA staff raises efficacy concerns over Intercept's liver disease drug
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
FDA staff raises efficacy concerns over Intercept's liver disease drug
Sep 11, 2024 6:11 AM

Sept 11 (Reuters) - The U.S. Food and Drug Administration's staff on

Wednesday raised efficacy concerns over Intercept Pharmaceuticals' liver disease

drug, which is awaiting traditional approval.

The reviewers, in briefing documents published on the FDA's website,

said the confirmatory trial for the drug did not provide evidence that it was

effective in patients with a rare condition called primary biliary cholangitis

(PBC).

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Form 8.3
Form 8.3
Nov 17, 2025
LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser:   Millennium International Management LP (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of...
Rehmann Announces Business Combination With  Teeling & Co.
Rehmann Announces Business Combination With Teeling & Co.
Nov 17, 2025
TROY, Mich., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Rehmann, a fully integrated professional advisory firm, announced today its plans to combine with Teeling & Co., a CPA firm in Tampa, effective January 1, 2026. The combination comes on the heels of Rehmann’s integration in June 2025 with Vero Beach accounting firm Kmetz, Elwell, Graham & Associates (KEGA) and demonstrates Rehmann’s...
Form 8.3
Form 8.3
Nov 17, 2025
BOSTON--(BUSINESS WIRE)--   Ap27 FORM 8.3 IRISH TAKEOVER PANEL OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE 1. KEY INFORMATION (a) Full name of discloser Weiss Asset Management LP (Investment Manager of Brookdale International Partners, L.P. and Brookdale Global Opportunity...
Form 8.3
Form 8.3
Nov 17, 2025
LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser:   Millennium International Management LP (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of...
Copyright 2023-2026 - www.financetom.com All Rights Reserved